FR2591895B1 - Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques - Google Patents

Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques

Info

Publication number
FR2591895B1
FR2591895B1 FR8518982A FR8518982A FR2591895B1 FR 2591895 B1 FR2591895 B1 FR 2591895B1 FR 8518982 A FR8518982 A FR 8518982A FR 8518982 A FR8518982 A FR 8518982A FR 2591895 B1 FR2591895 B1 FR 2591895B1
Authority
FR
France
Prior art keywords
immunotoxins
polysaccharide
lasting
vivo
patterns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8518982A
Other languages
English (en)
Other versions
FR2591895A1 (fr
Inventor
Pierre Casellas
Bernard Bourrie
Xavier Canat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR8518982A priority Critical patent/FR2591895B1/fr
Priority to US06/941,989 priority patent/US4911912A/en
Priority to IL80973A priority patent/IL80973A/xx
Priority to AT86402811T priority patent/ATE56977T1/de
Priority to ES86402811T priority patent/ES2018783B3/es
Priority to EP86402811A priority patent/EP0229564B1/fr
Priority to DE8686402811T priority patent/DE3674566D1/de
Priority to PT83947A priority patent/PT83947B/pt
Priority to AU66629/86A priority patent/AU611848B2/en
Priority to DK611986A priority patent/DK611986A/da
Priority to IE330686A priority patent/IE59650B1/en
Priority to AR86306244A priority patent/AR242590A1/es
Priority to ZA869573A priority patent/ZA869573B/xx
Priority to JP61302888A priority patent/JPH0780903B2/ja
Priority to KR1019860011020A priority patent/KR950007216B1/ko
Publication of FR2591895A1 publication Critical patent/FR2591895A1/fr
Application granted granted Critical
Publication of FR2591895B1 publication Critical patent/FR2591895B1/fr
Priority to US07/404,611 priority patent/US5106956A/en
Priority to GR90401135T priority patent/GR3001236T3/el
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR8518982A 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques Expired FR2591895B1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
FR8518982A FR2591895B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
US06/941,989 US4911912A (en) 1985-12-20 1986-12-15 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
IL80973A IL80973A (en) 1985-12-20 1986-12-15 Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
ES86402811T ES2018783B3 (es) 1985-12-20 1986-12-16 Glicoproteina modificada por oxidacion despues reduccion que inhibe los ribosomas, procedimiento de obtencion e inmunotoxinas que comportan tal glicoproteina.
EP86402811A EP0229564B1 (fr) 1985-12-20 1986-12-16 Glycoprotéines modifiées par oxydation puis réduction, inhibant les ribosomes, procédé d'obtention et immunotoxines comprenant une telle glycoprotéine
DE8686402811T DE3674566D1 (de) 1985-12-20 1986-12-16 Mittels oxidierung und anschliessender reduzierung modifizierte, ribosome inhibierende glykoproteine, verfahren zur herstellung derselben und ein solches glykoprotein enthaltende immunotoxine.
AT86402811T ATE56977T1 (de) 1985-12-20 1986-12-16 Mittels oxidierung und anschliessender reduzierung modifizierte, ribosome inhibierende glykoproteine, verfahren zur herstellung derselben und ein solches glykoprotein enthaltende immunotoxine.
AU66629/86A AU611848B2 (en) 1985-12-20 1986-12-17 Ribosome-inactivating glycoproteins, modified by oxydation of their osidic units and reduction, and in vivo prolonged- action immunotoxins containing such a glycoprotein
PT83947A PT83947B (pt) 1985-12-20 1986-12-17 Processo para a obtencao de glicoproteinas inibidoras dos ribosomas, modificadas por oxidacao das funcoes osidicas seguido e reducao
DK611986A DK611986A (da) 1985-12-20 1986-12-18 Riboson-inaktiverende glycoproteiner og immunotoksiner med forlaengetvirkning in vivo, der indeholder et saadant glycoprotein
IE330686A IE59650B1 (en) 1985-12-20 1986-12-18 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a gylcoprotein
ZA869573A ZA869573B (en) 1985-12-20 1986-12-19 Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and reduction,and in-vivo prolonged-action immunotoxins containing such a glycoprotein
AR86306244A AR242590A1 (es) 1985-12-20 1986-12-19 Un procedimiento de obtencion de una gpir modificada, y procedimiento para obtener una inmunotoxina utilizando dicha gpir modificada.
JP61302888A JPH0780903B2 (ja) 1985-12-20 1986-12-20 修飾糖タンパク質、当該修飾糖タンパク質の製造方法、当該修飾糖タンパク質を含む免疫毒素および当該免疫毒素を有効成分として含む抗ガン剤組成物
KR1019860011020A KR950007216B1 (ko) 1985-12-20 1986-12-20 오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
US07/404,611 US5106956A (en) 1985-12-20 1989-09-08 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
GR90401135T GR3001236T3 (en) 1985-12-20 1990-12-21 Glycoproteins modified by oxidation followed by reduction, which inhibit ribosomes, production process and immunotoxines containing such a glycoprotein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8518982A FR2591895B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques

Publications (2)

Publication Number Publication Date
FR2591895A1 FR2591895A1 (fr) 1987-06-26
FR2591895B1 true FR2591895B1 (fr) 1988-08-26

Family

ID=9326039

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8518982A Expired FR2591895B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques

Country Status (3)

Country Link
AR (1) AR242590A1 (fr)
FR (1) FR2591895B1 (fr)
ZA (1) ZA869573B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248040B1 (fr) * 1985-11-29 1993-03-24 Consolidated Pharmaceuticals Limited Composes conjugues a des anticorps de ricine
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps

Also Published As

Publication number Publication date
AR242590A1 (es) 1993-04-30
FR2591895A1 (fr) 1987-06-26
ZA869573B (en) 1987-08-26

Similar Documents

Publication Publication Date Title
NO307835B1 (no) Ikke-farmasøytisk polysakkaridkonjugat
FI905579A0 (fi) Modem med flera arbetssaett.
MX164779B (es) Mejoras a ductos de poliepoxido-polioxalquilenpoliamina glicidol modificados
DK0734212T3 (da) Kontaktflade med naturligt aftryk
DE68927610D1 (de) Antikörper-Arzneimittel Konjugale
DK186190A (da) Samlbaandet gmsk-modem
PT91671A (pt) Porta-chaves de argola
IT1246753B (it) Diga in foglio sgonfiabile
FR2591895B1 (fr) Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
MX164816B (es) Composicion y metodo para producir 1,3,5-trinitro-2,4,6-tripicrilbenceno
IT8822249A0 (it) Perfezionamenti apportati a borse e prodotti similari.
FR2591894B1 (fr) Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
IT1240753B (it) Albero a camme e metodo per produrlo.
KR900700425A (ko) 2,3-디플루오로페놀 유도체
IT1227454B (it) Procedimento e dispositivo per produrre un'apertura per tasca.
IT1183667B (it) Catena ad aghi e a griffa
ZA876594B (en) Triblock polymer and synthesis technique
FR2628333B1 (fr) Engin de glisse sur neige
IT1245851B (it) 13-desosso-4'-desossi-4'-iodoantracicline
FR2579710B1 (fr) Chaine constituee de maillons munis chacun d'un couple de colliers
BR8902378A (pt) Conjunto de selo mecanico
FR2629168B1 (fr) Chaine a double articulation
FR2627755B3 (fr) Article d'hygiene comportant un motif anti-inhibition
IT1188315B (it) Catena ad aghi e a griffa
IT8822917A0 (it) Orologio da polso incorporato in bracciale in corrispondenza dell'articolazione carpo-radiale

Legal Events

Date Code Title Description
ST Notification of lapse